References
  1. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320(13):828-834.
  2. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88(4):1501-1508.
  3. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343(11):750-758.
  4. J.H.F Falkenburg, I. Jedema Allo-reactive T cells for the treatment of hematological malignancies. Mol Oncol 2015;9(10):1894-903.
  5. Shanis D, Anandi P, Grant C, et al. Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. Bone Marrow Transplant 2018;53(1):78-83.
  6. Bipin N, Pamela S, Aarthi S, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation-implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008;14(9):1072-1075.